Bulletin
Investor Alert

New York Markets Close in:

Deciphera Pharmaceuticals Inc.

NAS: DCPH

GO
/marketstate/country/us

Countdown to close

 --Real time quotes

Sep 24, 2021, 3:06 p.m.

/zigman2/quotes/203556943/composite

$

32.80

Change

-0.56 -1.68%

Volume

Volume 206,400

Real time quotes

/zigman2/quotes/203556943/composite

Previous close

$ 33.36

$ 32.80

Change

-0.56 -1.68%

Day low

Day high

$31.78

$33.23

Open

52 week low

52 week high

$26.20

$68.40

Open

Company Description

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastr...

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.

Valuation

Price to Sales Ratio

75.64

Price to Book Ratio

6.05

Enterprise Value to Sales

63.27

Total Debt to Enterprise Value

0.01

Efficiency

Revenue/Employee

120,249.00

Income Per Employee

-761,397.00

Receivables Turnover

6.06

Total Asset Turnover

0.07

Liquidity

Current Ratio

8.34

Quick Ratio

8.26

Cash Ratio

7.89

Profitability

Gross Margin

87.25

Operating Margin

-644.36

Pretax Margin

-633.19

Net Margin

-633.19

Return on Assets

-42.14

Return on Equity

-48.89

Return on Total Capital

-47.62

Return on Invested Capital

-46.97

Capital Structure

Total Debt to Total Equity

5.74

Total Debt to Total Capital

5.43

Total Debt to Total Assets

4.86

Long-Term Debt to Equity

5.29

Long-Term Debt to Total Capital

5.00

Officers and Executives

Name Age Officer Since Title
Mr. Steven L. Hoerter 49 2018 President, Chief Executive Officer & Director
Mr. Thomas P. Kelly 49 2015 Chief Financial Officer
Dr. Matthew L. Sherman 64 2019 Chief Medical Officer & Executive Vice President
Dr. Daniel L. Flynn 66 - President, Chief Executive Officer & Director
Dr. Stephen B. Ruddy 56 2018 Chief Technical Officer

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
05/03/2021 Michael D. Taylor
Director
300   Disposition at $46.75 per share. 14,025
05/03/2021 Michael D. Taylor
Director
7,700   Disposition at $46.07 per share. 354,739
05/03/2021 Michael D. Taylor
Director
5,646   Derivative/Non-derivative trans. at $3.95 per share. 22,301
05/03/2021 Michael D. Taylor
Director
2,354   Derivative/Non-derivative trans. at $1.89 per share. 4,449
04/20/2021 James A. Bristol
Director
1,700   Disposition at $45.6 per share. 77,520
04/20/2021 James A. Bristol
Director
1,700   Derivative/Non-derivative trans. at $3.95 per share. 6,715
04/19/2021 James A. Bristol
Director
1,300   Disposition at $46.66 per share. 60,658
04/19/2021 James A. Bristol
Director
4,000   Disposition at $46.13 per share. 184,520
04/19/2021 James A. Bristol
Director
5,300   Derivative/Non-derivative trans. at $3.95 per share. 20,935
04/12/2021 James A. Bristol
Director
5,217   Disposition at $44.09 per share. 230,017
04/12/2021 James A. Bristol
Director
9,483   Disposition at $43.7 per share. 414,407
04/12/2021 James A. Bristol
Director
14,700   Derivative/Non-derivative trans. at $3.95 per share. 58,065
04/01/2021 Michael D. Taylor
Director
906   Disposition at $46.72 per share. 42,328
04/01/2021 Michael D. Taylor
Director
4,994   Disposition at $45.69 per share. 228,175
04/01/2021 Michael D. Taylor
Director
2,100   Disposition at $44.8 per share. 94,080
04/01/2021 Michael D. Taylor
Director
8,000   Derivative/Non-derivative trans. at $1.89 per share. 15,120
03/18/2021 Steven L. Hoerter
President and CEO; Director
2,450   Derivative/Non-derivative trans. at $43.19 per share. 105,815
03/18/2021 Steven L. Hoerter
President and CEO; Director
700   Derivative/Non-derivative trans. at $42.39 per share. 29,673
03/01/2021 Michael D. Taylor
Director
1,104   Disposition at $44.68 per share. 49,326
03/01/2021 Michael D. Taylor
Director
6,896   Disposition at $43.94 per share. 303,010
03/01/2021 Michael D. Taylor
Director
8,000   Derivative/Non-derivative trans. at $1.89 per share. 15,120
02/16/2021 Daniel L. Flynn
Chief Scientific Officer
11,100   Award at $0 per share. 0
02/16/2021 Matthew L. Sherman
EVP & Chief Medical Officer
11,100   Award at $0 per share. 0
02/16/2021 Thomas P. Kelly
Chief Financial Officer
11,100   Award at $0 per share. 0
02/16/2021 Daniel L. Flynn
Chief Scientific Officer
508   Disposition at $48.87 per share. 24,825
02/16/2021 Matthew L. Sherman
EVP & Chief Medical Officer
132   Disposition at $48.87 per share. 6,450
02/16/2021 Thomas P. Kelly
Chief Financial Officer
524   Disposition at $48.87 per share. 25,607
02/01/2021 Michael D. Taylor
Director
800   Disposition at $45.96 per share. 36,768
02/01/2021 Michael D. Taylor
Director
4,518   Disposition at $45.64 per share. 206,201
02/01/2021 Michael D. Taylor
Director
2,682   Disposition at $44.34 per share. 118,919
02/01/2021 Michael D. Taylor
Director
8,000   Derivative/Non-derivative trans. at $1.89 per share. 15,120
01/21/2021 Steven L. Hoerter
President and CEO; Director
1,078   Derivative/Non-derivative trans. at $25.4 per share. 27,381
/news/latest/company/us/dcph

MarketWatch News on DCPH

  1. Deciphera Pharmaceuticals started at buy with $75 stock price target at Stifel Nicolaus

    10:16 a.m. Dec. 3, 2020

    - Tomi Kilgore

  2. Callon, Fitbit, Genco Shipping, and Other 13D Filings

    10:30 p.m. Nov. 22, 2019

    - Barron's Online

  3. Deciphera Pharmaceuticals stock price target raised to $60 from $45 at SunTrust RH

    8:40 a.m. Aug. 14, 2019

    - Tomi Kilgore

  4. Deciphera Pharmaceuticals stock rockets 126% premarket after positive trial data for GIST treatment

    8:32 a.m. Aug. 13, 2019

    - Tomi Kilgore

  5. Deciphera Pharmaceuticals started at buy with $42 stock price target at Deutsche Bank

    2:17 p.m. July 18, 2019

    - Tomi Kilgore

  6. Deciphera Pharmaceuticals started at outperform with $47 stock price target at Raymond James

    8:25 a.m. Aug. 29, 2018

    - Tomi Kilgore

  7. Deciphera Pharmaceuticals started at buy with $60 stock price target at SunTrust RH

    7:54 a.m. July 5, 2018

    - Tomi Kilgore

  8. Deciphera Pharmaceuticals started at overweight with $30 stock price target at J.P. Morgan

    7:40 a.m. Oct. 23, 2017

    - Tomi Kilgore

/news/nonmarketwatch/company/us/dcph

Other News on DCPH

  1. 10-Q: DECIPHERA PHARMACEUTICALS, INC.

    4:16 p.m. Aug. 3, 2021

    - Edgar Online - (EDG = 10Q, 10K)

  2. Notable earnings after Tuesday's close

    5:35 p.m. Aug. 2, 2021

    - Seeking Alpha

  3. Deciphera Pharmaceuticals Q2 2021 Earnings Preview

    5:35 p.m. Aug. 2, 2021

    - Seeking Alpha

  4. 2 Beaten-Down Biotech Stocks That Could Bounce Back

    6:13 a.m. July 27, 2021

    - Motley Fool

  5. 3 Biotech Stocks That Could Double Soon

    6:44 a.m. July 21, 2021

    - Motley Fool

  6. Loading more headlines...

At a Glance

Deciphera Pharmaceuticals, Inc.

200 Smith Street

Waltham, Massachusetts 02451

Phone

1 7812096400

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2021

Revenue

$42.09M

Net Income

$-266.49M

2020 Sales Growth

68.3%

Employees

350.00

/news/pressrelease/company/us/dcph

Press Releases on DCPH

  1. Deciphera Pharmaceuticals, Inc. to Host Earnings Call

    2:30 p.m. May 4, 2021

    - ACCESSWIRE

  2. Deciphera Pharmaceuticals, Inc. to Host Earnings Call

    3:30 p.m. Feb. 9, 2021

    - ACCESSWIRE

  3. Loading more headlines...
Trending Tickers
  • /zigman2/quotes/200467500/composite NVDA+6.20%
  • /zigman2/quotes/201948298/composite BABA-5.69%
  • /zigman2/quotes/202092269/composite ENSC+36.10%
  • /zigman2/quotes/200164174/composite SNOA+74.50%
  • /zigman2/quotes/207683784/composite TIGR-10.38%
X
Powered by StockTwits
Link to MarketWatch's Slice.